While scientists and doctors against Corona virus are competing with time to develop drugs and vaccines, a story of failure emerged from the clinical trial database prepared by the World Health Organization …
US President Donald Trump commented, “A promising drug against Covid-19,” and it turned out that the first full-capacity clinical test of remdesivir did not result. It was stated that remdesiir, which has a worldwide stock shortage due to the positive perception created in many countries, was tried on 237 patients, which are the “gold standard”, and some of them did not receive the drug.
It was noted that, after the trials, remdesiir had no effect, the trials were terminated early due to “side effects”. This failure was included in the “clinical trial database” of the World Health Organization, which is open to the public. However, this report was soon removed.
“BECAUSE IT HAS BEEN FINISHED…”
Speaking on the subject, World Health Organization Spokesperson Tarik Jasarevic said: “The draft of the document, prepared by the experts conducting the research, was sent to WHO, but was removed immediately after the error was understood. We will re-open access to the report after other experts have looked at it. ”
In the report on the drug produced by the US company Gilead Sciences, the report said, “In this study, remdesivir did not have a clinical or virological benefit in adult Covid-19 patients in the hospital. Remdesivir ended early in 18 patients (11.6 percent of total patients because it had a side effect ”).
